ArticleJournal of neuro-oncology2018
Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Point/counterpoint: The role of re-resection in recurrent glioblastoma.Neuro-oncology · 2025Article
- Contribution of [Pharmaceuticals (Basel, Switzerland) · 2024Review
- Article
- The potential of amino acid PET imaging for prediction and monitoring of vorasidenib response in IDH-mutant gliomas.Neuro-oncology · 2024Article
- PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group.The Lancet. Oncology · 2024Review
- Review
- Boosting the acceptance ofEuropean journal of nuclear medicine and molecular imaging · 2023Article
- Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.European journal of nuclear medicine and molecular imaging · 2023Article
- Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.Neuro-oncology · 2023Article
- Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.Journal of neuro-oncology · 2023Review
- Review
- Review
- Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden.Annals of nuclear medicine · 2021Article
- Use of PET Imaging in Neuro-Oncological Surgery.Cancers · 2021Review
- Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II.Scientific reports · 2020Article
- Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas.Journal of neuro-oncology · 2020Article
- Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametricEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors.Molecules (Basel, Switzerland) · 2020Review
- Article
- Assessment ofNeuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMonitoring treatment response after chemotherapy of gadolinium-(Gd)-negative gliomas is challenging as conventional MRI often indicates no radiological changes. We hypothesize that
methodsSixty-one patients harboring Gd-negative WHO grade II or III glioma receiving alkylating agents (temozolomide or CCNU/procarbacine) were included. All patients underwent MRI and
results
conclusion
Indexed as
Identifiers
29948765What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.